Report Scope:
Antibody drug conjugates are mainly used to treat cancer and are safer and more effective than many other cancer therapies. This report focuses on the global market for antibody drug conjugate products and provides an updated review, including their basic design and application in various areas of the biomedical sciences. The report covers three main areas of application, breast cancer, lymphoma and other cancers, including acute myeloid leukemia. The scope of this study includes the current market for ADCs. The report also discusses regulatory aspects, current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations and opportunities and the latest trends in ADC market are also discussed in the report.
Also included in the report is an analysis of relevant patents and profiles of companies that lead the antibody drug conjugate product market. Seattle Genetics Inc., Takeda Pharmaceuticals Co. Ltd. and Genentech Inc. are the major players in the market for ADCs at present.
Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis, and sales are broken down geographically into North America, Europe, Asia-Pacific and the emerging markets. The application of ADCs in various types of cancer is discussed from both a commercial perspective and that of a research and development (R&D) perspective.
The report only covers antibody drug conjugates in which an antibody is conjugated with small-molecule cytotoxins (payload) through a linker. ADCs are a form of antibody conjugates. Other forms of antibody conjugates such as radioisotope conjugated with an antibody are beyond the scope of this report. The study also does not cover mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC.
Report Includes:
- An overview of the global market for antibody drug conjugates as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Chapter 4 Market Breakdown by Technology Type
Chapter 5 Market Breakdown by Application
Chapter 6 Industry Structure
Chapter 7 Market Breakdown by Region
Chapter 8 Patent Review/New Developments
Chapter 9 Analysis of Market Opportunities
Chapter 10 Company Profiles
Definitions
Global Market for the Application of ADCs in Treating Various Types of Cancers
Market Share
Breast Cancer
Lymphoma
Other Types of Cancer
Market Overview
Market Revenues
Market Overview
Market Revenues
Market Overview
Market Revenues
Market Leaders
Market Share
Market Overview
Market Revenues
Market for ADCs by Target Antigen
Market for CD-30 Targeting ADCs
Market for HER2 Targeting ADCs
Market for Other Antigen Targeting ADCs
Market Overview
Market Revenues
Market Overview
Market Revenues
Market Overview
Market Revenues
Patent Analysis
New Developments
Regulatory Issues
Patents by Year
Patents by Company
Patents by Country
Patents by Assignee
CMC-544
CDX-011
RG7596 (Polatuzumab Vedotin)
RG7593 (Pinatuzumab Vedotin)
PSMA ADC
IMGN853 (Mirvetuximab Soravtansine)
BT-062
Regulatory History of Approved ADCs
Regulatory Exclusivity
Other Regulatory Issues
Key Drivers
Key Challenges
Manufacturer Strategies
Patent Expiration
Targeted Nature of ADCs
Complexity of ADCs
Investor Confidence in Biologics
Increased Research on ADC Development
Other Factors
ABBVIE INC.
ABGENOMICS INTERNATIONAL INC.
ABZENA PLC
ADC BIOTECHNOLOGY LTD.
ADC THERAPEUTICS SA
AFFINICON APS
AGENSYS INC.
AMBRX INC.
AMGEN INC.
ANTIKOR BIOPHARMA LTD.
ASTELLAS PHARMA U.S. INC.
ASTRAZENECA PLC
BAYER AG
BIOTEST AG
BRISTOL-MYERS SQUIBB CO.
CATALENT PHARMA SOLUTIONS
CELLDEX THERAPEUTICS INC.
CELLTRION
CENTROSE
CYTOMX THERAPEUTICS INC.
DAIICHI SANKYO CO. LTD.
DALTON PHARMA SERVICES
ELI LILLY AND CO.
ESPERANCE PHARMACEUTICALS INC.
FORMATION BIOLOGICS
F. HOFFMANN-LA-ROCHE AG (ROCHE)
GENMAB A/S
GLAXOSMITHKLINE PLC
HEIDELBERG PHARMA GMBH
IMMUNOGEN INC.
IMMUNOMEDICS INC.
MERSANA THERAPEUTICS INC.
MILLENNIUM PHARMACEUTICALS INC. (NOW TAKEDA ONCOLOGY)
MORPHOSYS AG
NBE THERAPEUTICS
OXFORD BIOTHERAPEUTICS
PIERRE FABRE
PFIZER INC.
PHILOGEN SPA
PROGENICS PHARMACEUTICALS INC.
SANOFI
SEATTLE GENETICS INC.
SEVION THERAPEUTICS
SORRENTO THERAPEUTICS INC.
SUTRO BIOPHARMA INC.
SYNTHON BV
VIVENTIA BIOTECHNOLOGIES INC.
ZHEJIANG MEDICINE CO. LTD.
Chapter 11 Appendix: Abbreviations
List of Tables
Summary Table : Global Market for Antibody Drug Conjugates, by Region, Through 2021
Table 1 : History of Antibody Drug
Table 2 : Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody
Table 3 : Significant Antibody Drug Conjugate Payloads
Table 4 : Significant Antibody Drug Conjugate Linkers
Table 5 : Commercially Available Antibody Drug Conjugates: Key Components and Target Antigens
Table 6 : Antibody Drug Conjugates with Significant Market Potential During the Forecast Period
Table 7 : Global Market for Antibody Drug Conjugates, by Type of Payload, Through 2021
Table 8 : Global Market for Antibody Drug Conjugates, by Type of mAb, Through 2021
Table 9 : Global Market for Antibody Drug Conjugates, by Type of Linker, Through 2021
Table 10 : Global Market for Antibody Drug Conjugates, by Type of Cancer, Through 2021
Table 11 : Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016
Table 12 : Global Market for Breast Cancer Antibody Drug Conjugates, by Region, Through 2021
Table 13 : Global Market for Lymphoma Antibody Drug Conjugates, by Region, Through 2021
Table 14 : Global Market for Other Types of Antibody Drug Conjugates, by Region, Through 2021
Table 15 : Leading Manufacturers/Suppliers of Antibody Drug Conjugates, 2016
Table 16 : Global Market Shares of Manufacturers/Suppliers for Antibody Drug Conjugates, 2016
Table 17 : Global Market for Antibody Drug Conjugates, by Region, Through 2021
Table 18 : Significant Early Stage Clinical Trials on Adcetris, 2017
Table 19 : Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, Through 2021
Table 20 : Significant Early Stage Clinical Trials on Kadcyla, 2017
Table 21 : Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, Through 2021
Table 22 : Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, Through 2021
Table 23 : Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017
Table 24 : Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017
Table 25 : Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb. 2017
Table 26 : U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb. 2017
Table 27 : Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017
Table 28 : Number of Investigational New Drug Applications Filed, 2003-2016
Table 29 : ADCs in Research Pipeline as of Feb. 2017
Table 30 : Orphan Drug Designations Granted for Adcetris
Table 31 : Major Alliances for ADC Development
Table 32 : Abbreviations Used in Antibody Drug Conjugates
List of Figures
Summary Figure : Global Market for Antibody Drug Conjugates, by Region, 2014-2021
Figure 1 : Global Market for Antibody Drug Conjugates, by Type of Payload, 2014-2021
Figure 2 : Global Market for Antibody Drug Conjugates, by Type of mAb, 2014-2021
Figure 3 : Global Market for Antibody Drug Conjugates, by Type of Linker, 2014-2021
Figure 4 : Global Market for Antibody Drug Conjugates, by Type of Cancer, 2014-2021
Figure 5 : Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016
Figure 6 : Global Market for Breast Cancer Antibody Drug Conjugates, by Region, 2014-2021
Figure 7 : Global Market for Lymphoma Antibody Drug Conjugates, by Region, 2014-2021
Figure 8 : Global Market for Other Types of Antibody Drug Conjugates, by Region, 2014-2021
Figure 9 : Global Market Shares of Manufacturers/Suppliers of Antibody Drug Conjugates, 2016
Figure 10 : Global Market for Antibody Drug Conjugates, by Region, 2014-2021
Figure 11 : Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, 2014-2021
Figure 12 : Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, 2014-2021
Figure 13 : Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, 2014-2021
Figure 14 : Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017
Figure 15 : Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017
Figure 16 : Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb. 2017
Figure 17 : U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb. 2017
Figure 18 : Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017
+1 888 709 8757
Chat With Us